Last reviewed · How we verify
Study to Evaluate the Safety and Efficacy of Afamelanotide in Patients With Variegate Porphyria (VP)
The primary objective is to evaluate the impact of afamelanotide on the severity of skin disease in patients with Variegate Porphyria (VP). The secondary objectives are to evaluate the safety and tolerability of afamelanotide in patients with VP and evaluate the impact of afamelanotide on the quality of life of patients with VP.
Details
| Lead sponsor | Clinuvel Pharmaceuticals Limited |
|---|---|
| Phase | PHASE2 |
| Status | COMPLETED |
| Enrolment | 6 |
| Start date | Tue Mar 28 2023 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Thu Dec 28 2023 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Variegate Porphyria
Interventions
- Afamelanotide 16 MG
Countries
Netherlands